Deciphering Potential Pharmacological Mechanism of Sha-Shen-Mai-Dong Decoction on Primary Sjogren's Syndrome

Overview

Journal BMC Complement Med Ther

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2021 Mar 2

PMID 33648502

Citations 2

Authors

Yuepeng Jiang

Xiaoxuan Zhao

Jie Yu

Qiao Wang

Chengping Wen

Lin Huang

Affiliations

Soon will be listed here.

Abstract

Background: Sha-Shen-Mai-Dong decoction (SSMD) is a classical prescription widely used in primary Sjogren's Syndrome (pSS) therapy. This study aims to explore the potential pharmacological mechanism of SSMD on pSS.

Methods: Active components of SSMD were obtained from Traditional Chinese Medicine Integrative Database and Traditional Chinese Medicine Systems Pharmacology databases and targets of SSMD were predicted by Pharmmapper and STITCH database. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were carried out to explore the function characteristics of SSMD. The expression matrix of microarray of pSS was obtained from Gene Expression Omnibus and we obtained 162 differentially expressed genes (DEGs). Protein-protein interaction (PPI) networks were constructed to identify the hub targets. Principal component analysis (PCA) and molecular docking were conducted to further elucidate the possibility of SSMD for pSS.

Results: SSMD contained a total of 1056 active components, corresponding to 88 targets, among which peripheral myelin protein 2(PMP2), androgen receptor (AR) and glutamic acid decarboxylase 1(GAD1) are associated with multiple active components in SSMD and may be the core targets. Moreover, these targets were closely related to tissue pathological injury in SS, such as lacrimal gland, salivary gland and nervous system injury. GO and KEGG analysis showed that 88 targets enriched in REDOX process, transcriptional regulation and negative regulation of apoptosis process. Besides, SSMD may influence the cell proliferation, gene transcription through regulating Ras and cAMP-related signaling pathways. In addition, SSMD may show effects on immune regulation, such as macrophage differentiation, Toll-like receptor 4 signaling pathway and T-helper 1 in SS. Moreover, PPI network suggested that FN1, MMP-9 may be the hub targets in SSMD. Result of PCA and molecular docking analysis further determined the feasibility of SSMD in treating pSS.

Conclusion: SSMD can regulate multiple biological processes by virtue of its multiple active components, thus showing prominent advantage in the treatment of pSS. The discovery of active ingredients and targets in SSMD provides valuable resources for drug research and development for pSS.

Citing Articles

Therapeutic effect of modified zengye decoction on primary Sjogren's syndrome and its effect on plasma exosomal proteins.

Zeng Y, Peng X, Wang Y, Hou L, Ma W, Yang P Front Pharmacol. 2022; 13:930638.

PMID: 36091838 PMC: 9462528. DOI: 10.3389/fphar.2022.930638.

Is Chinese herbal formula (nourishing Yin therapy) effective and well tolerated as an adjunct medication to hydroxychloroquine in the treatment of primary Sjögren's syndrome? A meta-analysis of randomised controlled trials.

Li S, Ou R, Liu D, Chen Z, Wei S, Li X Ther Adv Chronic Dis. 2022; 13:20406223221077966.

PMID: 35251586 PMC: 8891913. DOI: 10.1177/20406223221077966.

References

Zhang Z, Cai Y, Zou F, Bie B, Pan Z . Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med. 2011; 17(11):1448-55. PMC: 3210928. DOI: 10.1038/nm.2442. View

Porola P, Laine M, Virtanen I, Pollanen R, Przybyla B, Konttinen Y . Androgens and integrins in salivary glands in Sjogren's syndrome. J Rheumatol. 2010; 37(6):1181-7. DOI: 10.3899/jrheum.091354. View

Vakrakou A, Polyzos A, Kapsogeorgou E, Thanos D, Manoussakis M . Perturbation of transcriptome in non-neoplastic salivary gland epithelial cell lines derived from patients with primary Sjögren's syndrome. Data Brief. 2018; 17:194-199. PMC: 5988450. DOI: 10.1016/j.dib.2017.12.023. View

Fox R . Sjögren's syndrome. Lancet. 2005; 366(9482):321-31. DOI: 10.1016/S0140-6736(05)66990-5. View

Ishikawa Y, Eguchi T, Skowronski M, Ishida H . Acetylcholine acts on M3 muscarinic receptors and induces the translocation of aquaporin5 water channel via cytosolic Ca2+ elevation in rat parotid glands. Biochem Biophys Res Commun. 1998; 245(3):835-40. DOI: 10.1006/bbrc.1998.8395. View

Yang L, Bai L, Wei F, Pang C, Wang X, Wang Y . Autoantibodies against interferon-γ reduce the frequency of pulmonary fibrosis and concentration of C-reactive protein in patients with primary Sjögren's syndrome. Mod Rheumatol. 2014; 25(2):325-7. DOI: 10.3109/14397595.2014.934418. View

Cortes-Troncoso J, Jang S, Perez P, Hidalgo J, Ikeuchi T, Greenwell-Wild T . T cell exosome-derived miR-142-3p impairs glandular cell function in Sjögren's syndrome. JCI Insight. 2020; 5(9). PMC: 7253014. DOI: 10.1172/jci.insight.133497. View

Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y . Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol. 2012; 26(1):105-17. DOI: 10.1016/j.berh.2012.01.012. View

Villalon L, Mamani M, Romanini F, Catalan Pellet A, Berra A . [Primary Sjögren's syndrome: Expression of NF-κB in minor salivary glands]. Reumatol Clin. 2011; 6(6):292-5. DOI: 10.1016/j.reuma.2009.10.009. View

10.

Sisto M, DAmore M, Caprio S, Mitolo V, Scagliusi P, Lisi S . Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands. Ann N Y Acad Sci. 2009; 1171:407-14. DOI: 10.1111/j.1749-6632.2009.04688.x. View

11.

Hashimoto H, Sohma H, Nagao M, Ishii S, Akino T . Elevation of carboxyl methylation activity on GTP-binding protein gamma-subunit in synovial tissues from rheumatoid arthritis: how does elevation of the methylation relate to the signal transduction system of rheumatoid arthritis?. J Orthop Sci. 2001; 5(5):470-4. DOI: 10.1007/s007760070025. View

12.

Perez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C . Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 2001; 43(12):2807-17. DOI: 10.1002/1529-0131(200012)43:12<2807::AID-ANR22>3.0.CO;2-M. View

13.

Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X, Tzioufas A . Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012; 8(7):399-411. DOI: 10.1038/nrrheum.2012.53. View

14.

Naveed M, Hejazi V, Abbas M, Kamboh A, Khan G, Shumzaid M . Chlorogenic acid (CGA): A pharmacological review and call for further research. Biomed Pharmacother. 2017; 97:67-74. DOI: 10.1016/j.biopha.2017.10.064. View

15.

Mariette X, Sibilia J, Roux S, Meignin V, Janin A . A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjögren's syndrome: over-expression of p53 and p21. Rheumatology (Oxford). 2002; 41(1):96-9. DOI: 10.1093/rheumatology/41.1.96. View

16.

Katsiougiannis S, Tenta R, Skopouli F . Autoimmune epithelitis (Sjögren's syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity. J Autoimmun. 2019; 104:102335. DOI: 10.1016/j.jaut.2019.102335. View

17.

Mizel D, Redman R, Panek R, Kulkarni A, Ward J, McCarthy J . Autoimmune Sjögren's-like lesions in salivary glands of TGF-beta1-deficient mice are inhibited by adhesion-blocking peptides. J Immunol. 1996; 157(3):1306-12. View

18.

Kong L, Ogawa N, Nakabayashi T, Liu G, DSouza E, McGuff H . Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 1997; 40(1):87-97. DOI: 10.1002/art.1780400113. View

19.

Sullivan D, Krenzer K, Sullivan B, Tolls D, Toda I, Dana M . Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency?. Invest Ophthalmol Vis Sci. 1999; 40(6):1261-5. View

20.

Suzuki T, Sullivan D . Estrogen stimulation of proinflammatory cytokine and matrix metalloproteinase gene expression in human corneal epithelial cells. Cornea. 2005; 24(8):1004-9. DOI: 10.1097/01.ico.0000160973.04072.a5. View